...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith AGM webcast 9/12/2018
Reply New Message
Back To Forum List View
Icon president Zenith AGM webcast 9/12/2018
8
BearDownAZ
Sep 10, 2018 05:56PM
Icon president Re: Zenith AGM webcast 9/12/2018
5
BearDownAZ
Sep 10, 2018 06:17PM
Icon president Re: Zenith AGM webcast 9/12/2018
3
BearDownAZ
Sep 11, 2018 11:45AM
Icon president Re: Zenith AGM webcast 9/12/2018
4
BearDownAZ
Sep 11, 2018 03:38PM
Re: Zenith AGM webcast 9/12/2018
4
Toinv
Sep 11, 2018 04:51PM
Icon president Re: Zenith AGM webcast 9/12/2018
2
BearDownAZ
Sep 12, 2018 01:59PM
Re: Zenith AGM webcast 9/12/2018
4
bfw
Sep 12, 2018 04:50PM

Thanks bfw. I wasn't expecting this until later tonight. I agree, there doesn't appear to be much new in the Zenith AGM slide deck other than updated treatment duration data in slide 16 (updated 8/22/18) for the combo mCRPC trial. Based on the frequent dose modifications of patient #6, I am guessing that patient #6 was the n=1 patient used in the CURATE.AI study. I will wait to comment any more on slide 16 until I hear the webcast narration.

BearDownAZ 

3 Recommendations
Re: Zenith AGM webcast 9/12/2018
5
tada
Sep 12, 2018 07:29PM
Re: Zenith AGM webcast 9/12/2018
2
rocketman2
Sep 12, 2018 08:50PM
Re: Zenith AGM webcast 9/12/2018
5
rocketman2
Sep 12, 2018 09:31PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply